COVID-19 Drug Treatment Concept

subject area of

• A living WHO guideline on drugs for covid-19  Academic Article
• A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)  Academic Article
• A real-time dashboard of clinical trials for COVID-19  Academic Article
• Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards  Academic Article
• Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials  Academic Article
• Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes  Academic Article
• Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis  Academic Article
• Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial  Academic Article
• Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT)  Academic Article
• Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study  Academic Article
• Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo  Academic Article
• Clinical trials of disease stages in COVID 19: complicated and often misinterpreted  Academic Article
• Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial  Academic Article
• Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial  Academic Article
• Deep learning identifies synergistic drug combinations for treating COVID-19  Academic Article
• Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments  Academic Article
• Dexamethasone and remdesivir: finding method in the COVID-19 madness  Academic Article
• Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19  Academic Article
• Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial  Academic Article
• Drug treatments for covid-19: living systematic review and network meta-analysis  Academic Article
• Dysregulated light/dark cycle impairs sleep and delays the recovery of patients in intensive care units: A call for action for COVID-19 treatment  Academic Article
• Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model  Academic Article
• Early Treatment with Pegylated Interferon Lambda for Covid-19  Academic Article
• Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs  Academic Article
• Effect of Early Treatment with Ivermectin among Patients with Covid-19  Academic Article
• Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial  Academic Article
• Efficacité et innocuité des agents antiviraux contre le SRAS-CoV-2, selon des données d’études sur la COVID-19 et d’autres infections virales aiguës : revue systématique et méta-analyse  Academic Article
• Efficacité et innocuité des corticostéroïdes dans le traitement de la COVID-19 selon des données pour la COVID-19, d’autres infections aux coronavirus, l’influenza, la pneumonie extrahospitalière et le syndrome de détresse respiratoire aiguë : revue systématique et méta-analyse  Academic Article
• Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis  Academic Article
• Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial  Academic Article
• Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial  Academic Article
• Ending COVID-19: progress and gaps in research—highlights of the July 2020 GloPID-R COVID-19 Research Synergies Meetings  Academic Article
• Fluvoxamine for the treatment of COVID-19 – Author's reply  Academic Article
• Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH  Academic Article
• Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society  Academic Article
• Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study  Academic Article
• Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19  Academic Article
• In COVID-19, tocilizumab reduces all-cause mortality at 28 d  Academic Article
• In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival  Academic Article
• In high-risk outpatients with COVID-19, remdesivir reduced COVID-19–related hospitalization or all-cause death at 28 d  Academic Article
• In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 d  Academic Article
• Influence of Prednisone on Inflammatory Biomarkers in Community‐Acquired Pneumonia: Secondary Analysis of a Randomized Trial  Academic Article
• Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021  Academic Article
• Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial  Academic Article
• Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial  Academic Article
• Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)  Academic Article
• Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)  Academic Article
• Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review  Academic Article
• Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group  Academic Article
• Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel  Academic Article
• Lessons learned from COVID-19 for the post-antibiotic future  Academic Article
• Managing drug shortages during a pandemic: tocilizumab and COVID-19  Academic Article
• My Kingdom for a Denominator, or at Least Enough Data  Academic Article
• One Solution for All: Searching for Universal Aptamers for Constantly Mutating Spike Proteins of SARS‐CoV‐2  Academic Article
• Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)  Academic Article
• Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial  Academic Article
• Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research  Academic Article
• Pregnancy and COVID ‐19: pharmacologic considerations  Academic Article
• Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD  Academic Article
• Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19  Academic Article
• Remdesivir for severe covid-19: a clinical practice guideline  Academic Article
• Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial  Academic Article
• Remdésivir chez les patients hospitalisés pour la COVID-19 au Canada: essai clinique randomisé et contrôlé  Academic Article
• Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial  Academic Article
• Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios  Academic Article
• Shortages of Palliative Care Medications in Canada during the COVID-19 Pandemic: Gambling with Suffering  Academic Article
• Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1)  Academic Article
• Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1)  Academic Article
• Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)  Academic Article
• Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3)  Academic Article
• Stroke and Thromboprophylaxis in the Era of COVID-19  Academic Article
• Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions  Academic Article
• The Protease Inhibitor Lopinavir, Boosted with Ritonavir, as Treatment for COVID-19: A Rapid Review  Academic Article
• The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19  Academic Article
• The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study  Academic Article
• The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials  Academic Article
• Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19  Academic Article
• Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19  Academic Article
• Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19  Academic Article
• Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?  Academic Article
• Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial  Academic Article
• Trials and tribulations: so many potential treatments, so few answers  Academic Article
• Twenty articles that critical care clinicians should read about COVID-19  Academic Article
• Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians  Academic Article
• Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)  Academic Article
• Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians  Academic Article
• Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)  Academic Article
• Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation  Academic Article
• Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?  Academic Article